CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
Clinical safety rating: safe
No significant drug interactions at recommended doses May cause somnolence although less than first-generation antihistamines.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
| Metabolism | Cetirizine is minimally metabolized in the liver; approximately 60% of the dose is excreted unchanged in urine. The primary metabolic pathway is oxidation to a carboxylic acid metabolite via CYP3A4, but this is a minor pathway. No significant first-pass metabolism. |
| Excretion | Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination. |
| Half-life | Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours). |
| Protein binding | 93% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.5–0.8 L/kg, indicating distribution into total body water; higher in pediatric patients relative to body weight. |
| Bioavailability | Oral: approximately 70% (first-pass metabolism minimal). |
| Onset of Action | Oral: 1 hour for symptom relief; peak effect at 2–4 hours. |
| Duration of Action | Symptom control persists for 24 hours, supporting once-daily dosing; full duration may extend to 24 hours due to sustained H1-receptor binding. |
| Molecular Weight | 461.81 |
| Action Class | Second-generation antihistamine |
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
| Dosage form | SOLUTION |
| Renal impairment | CrCl 30-49 mL/min: 5 mg orally once daily. CrCl <30 mL/min or ESRD (dialysis): contraindicated or 5 mg every other day with caution. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): no specific data; use with caution, consider dose reduction (e.g., 5 mg once daily). |
| Pediatric use | 6-12 months: 2.5 mg orally once daily. 1-2 years: 2.5 mg orally once or twice daily. 2-5 years: 2.5 mg orally once or twice daily, max 5 mg/day. 6-11 years: 5-10 mg orally once daily, max 10 mg/day. ≥12 years: adult dosing. |
| Geriatric use | No specific dose adjustment based on age alone; adjust for renal function. Start at 5 mg once daily and increase if needed, monitoring for sedation and anticholinergic effects. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use only if clearly needed. |
| 2nd trimester | Generally considered safe; avoid high doses. No known fetal risk. |
| 3rd trimester | Use caution near term due to potential for neonatal irritability or sedation. |
Clinical note
No significant drug interactions at recommended doses May cause somnolence although less than first-generation antihistamines.
| FDA category | Animal |
| Placental transfer | Cetirizine crosses the placenta; limited data indicate fetal serum concentrations approximately 25-50% of maternal levels. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Common Effects | urticaria |
| Serious Effects | Anaphylaxis, Angioedema, Seizures, Severe hypotension, Hepatotoxicity |
Hypersensitivity to cetirizine or any formulation componentSevere renal impairment (CrCl < 10 mL/min) for oral formulation
| Precautions | Avoid use in patients with renal impairment (CrCl < 10 mL/min) or end-stage renal disease; dose adjustment required for moderate impairment (CrCl 10–30 mL/min)., Use with caution in patients with hepatic impairment; dose reduction may be needed., May cause somnolence; patients should not drive or operate hazardous machinery until individual response is known., Concurrent use of alcohol or other CNS depressants may exacerbate sedation., Not recommended in children < 2 years of age due to increased risk of CNS adverse effects. |
| Food/Dietary |
Loading safety data…
| Cetirizine is excreted into breast milk in low amounts (estimated infant dose ~1.8% of maternal weight-adjusted dose). Not expected to cause adverse effects in most infants. Monitor for drowsiness or irritability in the infant. |
| Lactation Rating | L2 (Safe) |
| Teratogenic Risk | Limited data in humans; animal studies show no evidence of teratogenicity at doses up to 20 times the maximum recommended human dose. First trimester: insufficient human data; second and third trimesters: no reported fetal abnormalities. Category B. |
| Fetal Monitoring | No specific monitoring required; standard prenatal care. Observe for maternal drowsiness or anticholinergic effects. |
| Fertility Effects | No adverse effects on fertility reported in animal studies. Human data lacking. |
| Food does not significantly affect absorption, but taking with a meal may reduce stomach upset. Avoid alcoholic beverages in children old enough to consume them; alcohol can increase sedation. Grapefruit juice has no known interaction with cetirizine. |
| Clinical Pearls | Cetirizine is a second-generation antihistamine with minimal anticholinergic effects. It is FDA-approved for children ≥6 months for allergic rhinitis and ≥2 years for urticaria. Onset of action is within 1-2 hours; maximal effect at 4-6 hours. Dosing: 2.5 mg (½ tsp) for ages 6-23 months, 5 mg for ages 2-5 years, 5-10 mg for ages ≥6 years. Renal impairment: reduce dose in creatinine clearance <30 mL/min. Avoid concurrent CNS depressants. Cetirizine may cause drowsiness in some children; warn caregivers. |
| Patient Advice | Give the dose once daily at the same time each day. · May cause drowsiness; avoid driving or operating machinery until you know how your child reacts. · Do not exceed the recommended dose. · Keep the medicine out of reach of children. · If a dose is missed, skip it and give the next dose at the regular time. Do not double the dose. · Consult a doctor if symptoms worsen or do not improve after 3 days. |